1 / 36

Transmission & Staging (H1N1)v Pandemic

www.drsarma.in. H1N1v. Transmission & Staging (H1N1)v Pandemic. Dr. R V S N Sarma., MD., MSc. (Canada), FIMSA Consultant Physician & Chest Specialist. Acknowledgement.

jara
Download Presentation

Transmission & Staging (H1N1)v Pandemic

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. www.drsarma.in H1N1v Transmission & Staging (H1N1)v Pandemic Dr. R V S N Sarma., MD., MSc. (Canada), FIMSA Consultant Physician & Chest Specialist

  2. Acknowledgement • To compile this comprehensive presentation many resources on the internet are reviewed and relevant material like text, pictures, images, diagrams etc., are incorporated. • The main objective is to share the wide knowledge, at this hour of need, with all the physicians I come across and in turn help the patients and the community at large. • Scientific information from CDC, WHO, NIH, ECDC, BMJ, NEJM, Flu watch, SEARO, MOHFW, NCDC (NICD) is invaluable. • I record my sincere thanks and acknowledge using these resources. The references are listed at the end.

  3. What Should be Our Approach? Essential – Positive – Constructive Approach • Adequate awareness in general public – preventive measures • Comprehensive knowledge for the healthcare providers • Appropriate planning and responsibility of all involved Unwarranted – Misleading – Dangerous – Negative reactions • Fear, minute to minute monitoring of deaths, rumors • Media hype, Anxiety about infection and death by this flu • Panic, mania of mask use by one and all, and worry

  4. Types of Human Flu • Influenza A • Common, More Severe, Several Sub-types • Epidemics, Pandemics,  Mortality, High Mutagenicity • Influenza B • Less Severe, Less Frequent, No Sub types, Faithfully Human • Influenza C • Mild, Rare, No Sub types, Non fatal, Mild Illness in Children • Common Cold – Coryza & Other Viruses – Not Flu

  5. Influenza v/s Common Cold

  6. Influenza A Virus Types Neuraminidase (N) For Detachment Hemagglutinin (H) for Attachment • Orthomyxoviridae Family • Single stranded RNA virus • High mutagenicity, 8 proteins • H Ag types are 16 • N Ag types are 09 • So, 16 x 9 = 144 types possible • But only 3 types infect Humans • H1N1, H2N2 and H3N2 • Avian Flu Virus is H5N1 • Virus H1N1 - ‘Swine Flu’ Misnomer • Present Pandemic – (H1N1)v

  7. Seasonal v/s Pandemic Flu

  8. Avian, Swine and Human Flu Viruses

  9. The Novel H1N1 Virus • Orthomyxoviridae Family • Single Stranded RNA virus • High mutagenicity • Two viruses co-infect the same cell • New virus with segments of both • A mix of Avian, Swine and Human • This is genetic reassortment • Doesn’t require pigs as intermediary • ‘Swine Flu’ is now named H1N1v • Present Pandemic – (H1N1)v • This is less virulent than H5N1

  10. Antigenic Shift Antigenic Drift

  11. Seasonal Epidemic Flu v/s Pandemic H1N1

  12. Influenza Pandemics

  13. How Serious is the Current pandemic ? • We’re still learning about the severity of the novel H1N1 • At this time, there is not enough information to predict how severe this novel H1N1 flu outbreak will be in terms of illness and death or • It compares very similar to seasonal influenza. • Luckily most cases have been mild. Only few fatal cases • Most people recover without hospitalization or Tamiflu • It may mutate eventually and become more / less serious.

  14. Clinical Attack Rate

  15. Idealized National Curve For Planning Second Wave

  16. Global Scenario of the Current Pandemic CFR = (6260 ÷ 5,03,536) x 100 = 1.243%

  17. Global Picture of the Pandemic

  18. H1N1 in India As on 08thNovember 2009

  19. Natural History of H1N1v Mortality Rate = 150 ÷1,00,000 = 0.15% 1,00,000 50,000 Clinical Attack Rate = 10,000 ÷ 50,000 = 20% 10,000 1,000 CFR = 150 ÷ 10,000 or 1.5% 150

  20. Influenza A H1N1 Status as on 11th November 09 CFR = (508 ÷ 14851) x 100 = 3.42 %

  21. Symptoms of H1N1 Pandemic Flu • Very Similar to the Seasonal Flu and Not like Common Cold • Moderate to high fever • aches, muscle and joint pains • chills and fatigue • sore throat, head ache • cough • sneezing and running nose • shortness of breath, chest pain on breathing • diarrheas and vomiting (possible), loss of appetite

  22. When to Suspect H1N1 ? • Onset of acute febrile respiratory illness within 7 days of close contact with a person who has a confirmed case of H1N1 influenza A virus infection, or • Onset of acute febrile respiratory illness within 7 days of travel to a community (within the United States or internationally) where one or more H1N1 influenza A cases have been confirmed, or • Acute febrile respiratory illness in a person who resides in a community where at least one H1N1 influenza case has been confirmed.

  23. Clinical Presentations(in non-fatal cases)

  24. Age and Gender Distribution

  25. Epidemiological Parameters

  26. Global Experience of the Pandemic • Secondary attack rate in household contacts: 12 %. • Overall proportion of hospitalizations: 8 %. • Overall case fatality: 0.15 % or 1.5 per every 1000 cases • Most cases (58 %) highest incidence in 5–24 years age group, • Second highest incidence in children < 5 years • Most hospitalizations (34 %) in 5–24 years age group, • Highest age-specific hospitalization rate in children < 5 years • Most deaths in 5–24 years age group • The old are generally spared > 65

  27. The Current H1N1 Virus • Cocktail mix of Porcine, Avian and Human Influenza A Virus • Direct Airborne, No other routes so far • Fine droplets expelled during coughing and sneezing • Expectorated sputum and the dried secretion • Indirect - All items that have been in contact with a patient (Fomite) • Incubation Period (IP) – 3 to 7 days – Median 2-3 days • Contagious period – One day before symptoms to 7 days • Asymptomatic carrier state – None • Immunity – Life time for this type; No protection by seasonal flu

  28. Isolation and Quaranteen Isolation • Separation and restricted movement of ill persons with contagious disease, often in a hospital setting • Primarily individual level; Can be voluntary or mandated Quarantine • Separation and restriction of movement or activities of persons who are, not yet ill, have been exposed • Often at home, or residential facility or hospital Individual or community level; Can be voluntary or legally mandated

  29. Transmission

  30. Transmission

  31. Transmission

  32. The Aaa-chooh – (Sneezing)

  33. High Risk Groups for H1N1 • Diabetes • Pregnancy • Chronic Respiratory Illnesses , Neuromuscular disorders • Chronic cardio-vascular disease (? hypertension) • Seizure disorder and other neurodegenerative disease • Chronic renal disease stages III and IV • Cancer and immuno suppression including HIV • Morbid Obesity • More deaths in people <18 years of age

  34. Who are the High Risk Groups ? • Children < 5 years old; Persons aged 65 years or older • Children and adolescents (< 18 years) who are receiving long-term aspirin therapy and at risk for Reye syndrome • Pregnant women • Adults and children who have asthma, chronic pulmonary, cardiovascular, hepatic, hematological, neurologic, neuromuscular, or metabolic disorders such as diabetes; • Adults and children who have immuno-suppression (either due to medications or by HIV) • Residents of nursing homes and other chronic-care facilities.

  35. Diagnostic Testing • rRT-PCR Swine Flu assay– reverse transcriptase real time PCR • Highly specific test, 24 to 48 hours, costly Rs. 4,000, detects viral multiplication, can identify the novel H1N1 correctly • Confirmatory test, sensitivity is also quite high 85%, Quantitative • RIDT (Rapid Influenza Diagnostic Test) – Not Recommended • point of care, 1 hour, less cost (Rs 700), card test, detects viral protein • Sensitivity low 10 to 70% - A negative result can’t exclude Influenza • Can not distinguish between Influenza B or A or A sub types • Specificity – 80% - can confirm Influenza infection – not the type • If positive – needs a confirmatory test to identify the type

  36. This is the best way to contain H1N1 Namaskaar

More Related